Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windlas BiotechNSE:WINDLAS +1.04%89 Debt-to-Equity is 0.06 as of Mar. 2026, which is at its 10-year median of 0.06. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹952.34 (Fairly Valued). The stock has 1 warning sign investors should review. Among 811 Drug Manufacturers companies, Windlas Biotech ranks better than 80.64% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Windlas Biotech's Debt-to-Equity or its related term are showing as below:
NSE:WINDLAS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.06 Max: 0.17
Current: 0.06
During the past 8 years, the highest Debt-to-Equity Ratio of Windlas Biotech was 0.17. The lowest was 0.01. And the median was 0.06.
NSE:WINDLAS's Debt-to-Equity is ranked better than 80.64% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs NSE:WINDLAS: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Windlas Biotech Debt-to-Equity Related Terms
Windlas Biotech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Debt-to-Equity of 0.06 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Windlas Biotech and its competitors. This is near median its historical median of 0.06. Over the past decade, Windlas Biotech's Debt-to-Equity has ranged from 0.01 to 0.17. According to the industry distribution chart, Windlas Biotech ranks #157 out of 811 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is Windlas Biotech's Debt-to-Equity too high?
Windlas Biotech's current Debt-to-Equity of 0.06 is near median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.17. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Windlas Biotech's value of 0.06 is 78.6% below this industry median. Based on the distribution chart, Windlas Biotech ranks #157 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #157 out of 811 companies for Debt-to-Equity. This places Windlas Biotech in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Windlas Biotech's value of 0.06 is 78.6% below this benchmark. Historically, Windlas Biotech's own Debt-to-Equity has ranged from 0.01 to 0.17 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.28, Windlas Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Debt-to-Equity of 0.06 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Debt-to-Equity is 0.06, which is near median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹952.34, compared to a current price of ₹882.85 — trading 7.3% below its estimated fair value. The current Debt-to-Equity is 0.06, which is near median its 10-year median of 0.06 and 78.6% below the Drug Manufacturers industry median of 0.28. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Debt-to-Equity is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹882.85 is trading 7.3% below its estimated GF Value™ of ₹952.34.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Debt-to-Equity: 0.06 (near median its 10-year median of 0.06)
GF Value™: ₹952.34 vs. price of ₹882.85 (7.3% below fair value)
Industry Position: 78.6% below the Drug Manufacturers median (#157 of 811)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score
Get the complete analysis for NSE:WINDLAS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
